Clinical Trial Update: Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of an anti-OX40 antibody with ipilimumab in metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-OX40 antibody (anti-OX40 antibody)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: WITHDRAWN